Pay in 4 interest-free payments of $5.10 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
independently extracted the following information from the included meta-analyses: first author, publication year, intervention type, study population, study design, number of included trials, number of participants, outcomes, effect model, effect size, heterogeneity, and publication bias
RiskBenefit Perspective Despite theoretical concerns, the clinical reality is clear: GLP-1 therapies produce substantial weight loss Improve glycemic control and cardiometabolic outcomes Reduce cardiovascular risk in multiple studies When evaluating carcinogenicity risk, current evidence suggests: Strong rodent signals exist but may not translate to humans Long-term human data has not confirmed increased thyroid cancer risk Regulatory warnings remain precautionary rather than confirmatory Conclusion The GLP-1 receptor agonist classfrom Liraglutide to next-generation oral agents like Orforglipronrepresents one of the most transformative areas in metabolic medicine
It does not make sense to allocate more, as the upside for the distributors is limited
10.1161/01.cir.103.23.2799 36 Du PreezA.OnoratoD.EibenI.MusaelyanK.EgelandM.ZunszainP
PMID: 28051332
US$ 29.11
US$ 24.63
US$ 25.58
